DOCSLIB.ORG

Molecular Associations Between the T-Lymphocyte Antigen Receptor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molecular Associations Between the T-Lymphocyte Antigen Receptor Proc. Nati. Acad. Sci. USA Vol. 89, pp. 2945-2949, April 1992 Immunology Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5 (signal transduction/tyrosine phosphorylation/T-cell antigen receptor/lck/fyn) ALBERTUS D. BEYERS, LOUISE L. SPRUYT, AND ALAN F. WILLIAMS Medical Research Council Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, England Communicated by James Gowans, December 20, 1991 ABSTRACT The T-cell antigen receptor (TCR) complex is CD2 and CD5 do not have enzymatic activities, nor are they the key structure involved in signal transduction in T cells. To known to associate with Tyr kinases, but their activities analyze associations between the TCR complex and other might be due to associations with the TCR complex. An molecules, immunoprecipitations were carried out, followed by association between CD2 and CD3 in digitonin lysates of phosphorylation of molecules in vitro by tyrosine kinases asso- human T cells was reported (21), but these findings have not ciated with the precipitated molecules. This provided a sensi- proven to be routinely reproducible (M. H. Brown, personal tive assay for molecular complexes, and associations were communication). demonstrated between the TCR complex and the surface Given (i) the well-documented association of p56Ick with antigens CD2, CD4, or CD8 and CD5 in normal rat T cells. The CD4/CD8 (reviewed in ref. 5), (ii) the association of p59fYn complexes were readily seen in immunoprecipitates from BrU with the TCR complex (13), and (iii) the fact that the ; chain 96 but not Nonidet P40detergent extracts. The multimolecular and the CD3 £ and y chains are substrates for p56lck (4) and complexes are associated with the internal tyrosine kinases p59fy1 (13), we decided to use the sensitivity of in vitro p56kk and p59VY. The presence of p56kk associated with CD4 immune complex kinase assays to analyze associations ofthe or CD8 was also examined in early thymocytes, natural killer TCR complex with other cell-surface molecules. A physical cells, and macrophages. The kinase was present in all cases association ofCD4 and CD8 as well as CD2 and CD5 with the except that of normal macrophages. TCR complex is demonstrated. We propose that this array of transmembrane cell-surface molecules forms a signaling The earliest known events in T-cell activation result in complex in conjunction with the p56lck and p59fyn kinases. phosphorylation oftyrosine residues of cytoplasmic proteins by tyrosine kinases (Tyr kinases) (1). It is believed that phospholipase C,1 is activated by phosphorylation (2, 3) and MATERIALS AND METHODS that another substrate is the ' chain of the T-cell antigen Animals and Antibodies. Thymuses, cervical lymph nodes, receptor (TCR) complex (4, 5). Tyr kinases of the src family and peritoneal exudate cells were from AO-RT1u rats. The rat that are particularly associated with T cells include p56lck and NK cell line A181 arose in a Fischer rat (18). mAbs used (refs. p59fyn (6, 7). The p56lck protein binds to the cytoplasmic 22-24 unless otherwise stated) were W3/25 (IgG1) and OX-70 domains of the CD4 and CD8 molecules (4, 8-10), and this (IgG2a) noncompetitive anti-rat CD4 mAbs; OX-1 (IgG1) association is required for efficient signal transduction via the anti-rat CD45 mAb; OX-2 (IgG1) mAb against an immuno- TCR complex (11, 12). A key role for p59f1n in T-cell signal globulin-related molecule of rat thymocytes and brain (25); transduction is also indicated by the findings that this protein OX-8 (IgG1) anti-rat CD8 a-chain mAb; OX-18 (IgG1) anti-rat is associated with the TCR (13) and that transgenic expres- RT1A mAb (nonpolymorphic); OX-19 (IgG1) anti-rat CD5 sion of p59fyn in thymocytes leads to enhanced signaling in mAb; OX-20 (IgG1) rat anti-mouse immunoglobulin K chain; these cells in response to anti-CD3 monoclonal antibodies OX-21 (IgG1) anti-human C3b inactivator; OX-34 (IgG2a) (mAbs) (6). Taken together, the data suggest that the TCR and anti-rat CD2 mAb; OX-44 (IgG1) anti-rat CD53 mAb; OX-47 the CD4/CD8 coreceptors interact together to transmit sig- (IgG1) against a rat immunoglobulin superfamily glycopro- nals by coupling to the internal Tyr kinases p56lck and p59fyn. tein; OX-49 (IgG2a) and OX-50 (IgGl) anti-rat CD44 mAbs; Crosslinking of the CD2 and CD5 T-cell antigens can also OX-52 (isotype unknown), a rat T-cell marker (26); W3/13 have effects on T-cell activation (14). Certain combinations of (IgG1) and OX-56 (IgG2b) anti-rat CD43 mAbs; PY-20 (IgG1) anti-CD2 mAbs induce mitogenesis in T cells, and the same anti-phosphotyrosine mAb (ICN); R73 (IgGl) anti-rat TCR, activation of signal transduction parameters occurs as is seen pan-a/,B-chain mAb; and 1F4 (IgM) anti-rat CD3 mAb. with activation via the TCR (15, 16). For these events, the Polyclonal rabbit antisera were: anti-CD3 E chain (27) and cytoplasmic domain of CD2 is required (15, 17), and it also anti-CD5 (raised against a 22-mer peptide corresponding to seems that a functional T-cell receptor is required for cells to the C-terminal 21 amino acids of CD5), provided by D. Y. be efficiently activated via CD2 (15, 18). Crosslinking of CD5 Mason (Department of Haematology, John Radcliffe Hospi- antigen by mAbs potentiates T-cell proliferation in response tal, Oxford); anti-CD3 r chain (16), provided by D. A. to mitogens, alloantigens, or anti-CD2 mAbs (14, 17). Again Cantrell (Imperial Cancer Research Fund, London); anti- expression of the TCR complex is required for effects me- p59fyn [a mixture of fynl and fyn2 (28), provided by S. A. diated by CD5 (19), and in turn CD5 may be required for Courtneidge, European Molecular Biology Laboratory, activation via the TCR, since rat cells that were down- Heidelberg]; anti-p56lck, against a peptide corresponding to regulated in expression ofCD5 by administration ofanti-CD5 amino acids 39-64 of murine provided J. B. mAb in vivo did not proliferate in response to alloantigens or p56lck (9), by other mitogenic stimuli (20). The cytoplasmic domains of Abbreviations: Tyr kinase, tyrosine kinase; BSA, bovine serum albumin; GAP, GTPase-activating protein; IL-2, interleukin 2; mAb, The publication costs of this article were defrayed in part by page charge monoclonal antibody; NK, natural killer; RAM, rabbit anti-mouse payment. This article must therefore be hereby marked "advertisement" IgG antibodies; TCR, T-cell receptor for antigen; NP-40, Nonidet in accordance with 18 U.S.C. §1734 solely to indicate this fact. P-40. 2945 2946 Immunology: Beyers et al. Proc. Natl. Acad. Sci. USA 89 (1992) Bolen (Bristol-Myers Squibb, Princeton); anti-GTPase- Magnetic Cell Sorting and Flow Cytometric Analysis. Thy- activating protein (anti-GAP), raised against a glutathione mocytes (2 x 10) were incubated on ice for 45 min in 5 ml S-transferase fusion protein containing the SH2 and SH3 of PBS/BSA containing 2 pg of biotinylated W3/25 (anti- domains ofGAP, provided by J. Downward (Imperial Cancer CD4), 2 pg of biotinylated OX-44 (anti-CD53), and 1 pg of Research Fund); and rabbit anti-mouse immunoglobulin R73 (anti-TCR) mAbs per ml. Cells were washed twice in (RAM), provided by S. Simmonds of the Medical Research PBS containing 0.01% NaN3 and 5 mM EDTA (PBS/NaN3/ Council Cellular Immunology Unit. EDTA) and then incubated on ice for 45 min in 5 ml of Immunoprecipitations and Immune Complex Kinase As- PBS/NaN3/EDTA containing 5 pg offluorescein-conjugated says. Cells (5 x 107, or numbers as in the text) were avidin per ml. After two more washes in PBS/NaN3/EDTA, preincubated with mAbs (10 ,g of immunoglobulin or 10 pJ cells were incubated for 10 min in 5 ml of the same buffer of ascites) in 500 jl of phosphate-buffered saline (PBS) containing 75 Al of biotinylated superparamagnetic micro- containing 0.25% (vol/vol) bovine serum albumin (BSA) for beads (Becton Dickinson). Unlabeled cells were purified by 30 min at 4°C. Cells were pelleted for 15 sec in a microcen- repeated passages over a magnetic column (MACS, Becton trifuge and solubilized in 1 ml of a buffer (10 mM Tris HCl, Dickinson). About 2 x 107 CD4- CD53- TCR- cells were pH 7.4/150 mM NaCl/1 mM EDTA/1 mM phenylmethyl- obtained, and purity was evaluated by flow cytometry (FAC- sulfonyl fluoride/1 mg ofBSA per ml) containing 1% Nonidet SCAN, Becton Dickinson). For purification of CD2- TCR- P-40 (NP-40) (Sigma) or 1% Brij 96 (Sigma) for 30 min on ice. peritoneal cells (1.2 x 108), biotinylated OX-34 (anti-CD2) and Lysates were centrifuged at 12,000 x g for 10 min at 4°C. biotinylated R73 (anti-TCR) mAbs were used, and amounts of Supernatants were precleared by rotation with 100 ,u of reagents were scaled down according to cell numbers. Sepharose CL-4B beads (10% vol/vol) with OX-2 mAb attached for 30 min at 4°C. Supernatants were added to 100 RESULTS y4 ofprotein A-Sepharose CL-4B (1o vol/vol) containing 40 pg of bound RAM and rotated for 1 hr at 4°C. Beads were Effect of Two Detergents on the Association of p563 with washed three times in 1 ml of lysis buffer and twice in 1 ml CD4 and CD8 in Thymocytes. Our initial interest was to study ofassay buffer [25 mM Hepes (pH 7.5) containing 0.1% NP-40 p56 ck associated with CD4 and CD8 in early thymocytes.
Load more

Recommended publications
  • Costimulation of T-Cell Activation and Virus Production by B7 Antigen on Activated CD4+ T Cells from Human Immunodeficiency Virus Type 1-Infected Donors OMAR K
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 11094-11098, December 1993 Immunology Costimulation of T-cell activation and virus production by B7 antigen on activated CD4+ T cells from human immunodeficiency virus type 1-infected donors OMAR K. HAFFAR, MOLLY D. SMITHGALL, JEFFREY BRADSHAW, BILL BRADY, NITIN K. DAMLE*, AND PETER S. LINSLEY Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121 Communicated by Leon E. Rosenberg, August 3, 1993 (receivedfor review April 29, 1993) ABSTRACT Infection with the human immunodeficiency sequence (CTLA-4) (34), a protein structurally related to virus type 1 (HIV-1) requires T-cefl activation. Recent studies CD28 but only expressed on T cells after activation (12). have shown that interactions of the T-lymphocyte receptors CTLA-4 acts cooperatively with CD28 to bind B7 and deliver CD28 and CTLA-4 with their counter receptor, B7, on antigen- T-cell costimulatory signals (13). presenting cells are required for optimal T-cell activation. Here Because of the importance of the CD28/CTLA-4 and B7 we show that HIV-1 infection is associated with decreased interactions in immune responses, it is likely that these expression of CD28 and increased expression of B7 on CD4+ interactions are also important during HIV-1 infection. Stud- T-cell lines generated from seropositive donors by afloantigen ies with anti-CD28 monoclonal antibodies (mAbs) suggested stimulation. Loss of CD28 expression was not seen on CD4+ a role for CD28 in up-regulating HIV-1 long terminal repeat- T-ceU lines from seronegative donors, but up-regulation of B7 driven transcription of a reporter gene in leukemic cell lines expression was observed upon more prolonged culture.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Papers J Clin Pathol: First Published As 10.1136/Jcp.49.7.539 on 1 July 1996
    Clin Pathol 1996;49:539-544 539 Papers J Clin Pathol: first published as 10.1136/jcp.49.7.539 on 1 July 1996. Downloaded from Differential expression of T cell antigens in normal peripheral blood lymphocytes: a quantitative analysis by flow cytometry L Ginaldi, N Farahat, E Matutes, M De Martinis, R Morilla, D Catovsky Abstract diagnosis by comparison with findings in Aims-To obtain reference values of the normal counterparts. level of expression of T cell antigens on ( Clin Pathol 1996;49:539-544) normal lymphocyte subsets in order to disclose differences which could reflect Keywords: flow cytometry, T cell antigens, peripheral their function or maturation stages, or blood lymphocytes. both. Methods-Peripheral blood from 15 healthy donors was processed by flow The most common use of flow cytometry is to cytometry with triple colour analysis. For determine the percent of "positive" or "nega- each sample phycoerythrin (PE) conju- tive" cells for each antigen in different cell gated CD2, CD4, CD5, CD8, and CD56 populations. However, valuable information is monoclonal antibodies were combined lost when the relative intensities of the positive with Cy5-R-phycoerythrin (TC) conju- cells, reflecting antigenic densities, are not considered. A cell population with a well gated CD3 and fluorescein isothiocyanate http://jcp.bmj.com/ (FITC) conjugated CD7; CD2- and defined phenotype, positive for one antigen, CD7-PE were also combined with might be heterogeneous with regard to its level CD3-TC and CD4-FITC. Standard mi- of expression. This may reflect different crobeads with different capacities to bind functional or maturational states, or both, or mouse immunoglobulins were used to identify subpopulations on the basis of the dif- convert the mean fluorescence intensity ferent numbers of molecules of antigen per cell.
    [Show full text]
  • CD18) in a Patient with Leukocyte Adhesion Molecule (Leu-CAM) Deficiency
    Point mutations impairing cell surface expression of the common beta subunit (CD18) in a patient with leukocyte adhesion molecule (Leu-CAM) deficiency. M A Arnaout, … , D G Tenen, D M Fathallah J Clin Invest. 1990;85(3):977-981. https://doi.org/10.1172/JCI114529. Research Article The leukocyte adhesion molecules CD11a/CD18, CD11b/CD18, and CD11c/CD18 (Leu-CAM) are members of the integrin receptor family and mediate crucial adhesion-dependent functions in leukocytes. The molecular basis for their deficient cell surface expression was sought in a patient suffering from severe and recurrent bacterial infections. Previous studies revealed that impaired cell surface expression of Leu-CAM is secondary to heterogeneous structural defects in the common beta subunit (CD18). Cloning and sequencing of complementary DNA encoding for CD18 in this patient revealed two mutant alleles, each representing a point mutation in the coding region of CD18 and resulting in an amino acid substitution. Each mutant allele results in impaired CD18 expression on the cell surface membrane of transfected COS M6 cells. One substitution involves an arginine residue (Arg593----cysteine) that is conserved in the highly homologous fourth cysteine-rich repeats of other mammalian integrin subfamilies. The other substitution involves a lysine residue (Lys196----threonine) located within another highly conserved region in integrins. These data identify crucial residues and regions necessary for normal cell surface expression of CD18 and possibly other integrin beta subunits and define a molecular basis for impaired cell surface expression of CD18 in this patient. Find the latest version: https://jci.me/114529/pdf Rapid Publication Point Mutations Impairing Cell Surface Expression of the Common ,B Subunit (CD18) in a Patient with Leukocyte Adhesion Molecule (Leu-CAM) Deficiency M.
    [Show full text]
  • The Immunological Synapse and CD28-CD80 Interactions Shannon K
    © 2001 Nature Publishing Group http://immunol.nature.com ARTICLES The immunological synapse and CD28-CD80 interactions Shannon K. Bromley1,Andrea Iaboni2, Simon J. Davis2,Adrian Whitty3, Jonathan M. Green4, Andrey S. Shaw1,ArthurWeiss5 and Michael L. Dustin5,6 Published online: 19 November 2001, DOI: 10.1038/ni737 According to the two-signal model of T cell activation, costimulatory molecules augment T cell receptor (TCR) signaling, whereas adhesion molecules enhance TCR–MHC-peptide recognition.The structure and binding properties of CD28 imply that it may perform both functions, blurring the distinction between adhesion and costimulatory molecules. Our results show that CD28 on naïve T cells does not support adhesion and has little or no capacity for directly enhancing TCR–MHC- peptide interactions. Instead of being dependent on costimulatory signaling, we propose that a key function of the immunological synapse is to generate a cellular microenvironment that favors the interactions of potent secondary signaling molecules, such as CD28. The T cell receptor (TCR) interaction with complexes of peptide and as CD2 and CD48, which suggests that CD28 might have a dual role as major histocompatibility complex (pMHC) is central to the T cell an adhesion and a signaling molecule4. Coengagement of CD28 with response. However, efficient T cell activation also requires the partici- the TCR has a number of effects on T cell activation; these include pation of additional cell-surface receptors that engage nonpolymorphic increasing sensitivity to TCR stimulation and increasing the survival of ligands on antigen-presenting cells (APCs). Some of these molecules T cells after stimulation5. CD80-transfected APCs have been used to are involved in the “physical embrace” between T cells and APCs and assess the temporal relationship of TCR and CD28 signaling, as initiat- are characterized as adhesion molecules.
    [Show full text]
  • (12) United States Patent (405
    USOO6291239B1 (12) United States Patent (10) Patent No.: US 6,291,239 B1 Prodinger et al. (45) Date of Patent: Sep. 18, 2001 (54) MONOCLONAL ANTIBODY Recess Formed Between SCR1 and SCR 2 of Complement Receptor Type Two', Prodinger. (76) Inventors: Wolfgang Prodinger, Kirschentalgasse Immunopharmacology, vol. 38, No. 1-2, Dec., 1997, pp. 16, A-6020 Innsbruck; Michael 141-148, XP002089604, “Expression in Insect Cells of the Schwendinger, Semmelweisgasse 4, Functional Domain of CD21 (Complement Receptor Type A-7100 Neusiedl/See, both of (AT) Two) as a Truncated... ", Prodinger. Journal of Immunology, vol. 156, No. 7 Apr. 1, 1996, pp. (*) Notice: Subject to any disclaimer, the term of this 2580–2584, XP002089605, “Ligation of the Functional patent is extended or adjusted under 35 Domain of Complement Receptor Type 2 (CR2, CD21) is U.S.C. 154(b) by 0 days. Relevant for Complex . , Prodinger. Journal of Immunology, vol. 154, No. 10, May 15, 1995, pp. (21) Appl. No.: 09/276,296 5426–5435, XP002089606, “Characterization of a Comple (22) Filed: Mar. 25, 1999 ment Receptor 2 (CR2, CD21) Ligand Binding Site for C3”, H. Molina et al. (51) Int. Cl. ............................... C12N 5/06; C12O 1/70; Journal of Immunology, vol. 161, Nov. 1, 1998, pp. G01N 33/53; CO7K 16/00; A61K 39/395 4604–4610, XP002089607, “Characterization of C3dg Binding to a Recess Formed Between Short Consensus (52) U.S. Cl. ............................ 435/339.1; 435/5; 435/7.1; Repeats 1 and 2 ... ', Prodinger. 435/334; 530/388.1; 530/388.35; 424/141.1; 424/143.1; 424/159.1 Primary Examiner Hankyel T.
    [Show full text]
  • CD20-Positive Peripheral T-Cell Lymphoma: Report of a Case After Nodular Sclerosis Hodgkin’S Disease and Review of the Literature Renee L
    CD20-Positive Peripheral T-Cell Lymphoma: Report of a Case after Nodular Sclerosis Hodgkin’s Disease and Review of the Literature Renee L. Mohrmann, M.D., Daniel A. Arber, M.D. Division of Pathology, City of Hope National Medical Center, Duarte, California CASE REPORT We present a case of peripheral T-cell lymphoma co-expressing CD3 and CD20, as well as demon- A 47-year-old man presented in 1993 with a brief strating T-cell receptor gene rearrangement, in a history of right axillary lymph node enlargement patient who had been diagnosed with nodular scle- and mild fatigue. Biopsy showed nodular sclerosis rosis Hodgkin’s disease 5 years previously. Although Hodgkin’s disease. He was treated with six courses 15 cases of CD20-positive T-cell neoplasms have of mechlorethamine, vincristine, procarbazine, been previously reported in the literature, this is the prednisone/doxorubicin, bleomycin, vinblastine first report of CD20-positive T-cell lymphoma oc- chemotherapy over a period of 6 months. Clinical curring subsequent to treatment of Hodgkin’s dis- remission was achieved for 5 years. In early 1998, the patient noticed enlargement of lymph nodes in ease. The current case affords an opportunity to the posterior cervical region, which were followed review the rarely reported expression of CD20 in clinically for several months. Weight loss of 15 lbs., T-cell neoplasms as well as the relationship between fatigue, and flu-like symptoms ensued. The lymph Hodgkin’s disease and subsequently occurring non- nodes became firmer to palpation and were biop- Hodgkin’s lymphomas. In addition, the identifica- sied, showing peripheral T-cell lymphoma, diffuse tion of this case supports the suggestion that the use large-cell type.
    [Show full text]
  • Immunological Synapse Formation Licenses CD40-CD40L Accumulations at T-APC Contact Sites1
    The Journal of Immunology Immunological Synapse Formation Licenses CD40-CD40L Accumulations at T-APC Contact Sites1 Judie Boisvert, Samuel Edmondson, and Matthew F. Krummel2 The maintenance of tolerance is likely to rely on the ability of a T cell to polarize surface molecules providing “help” to only specific APCs. The formation of a mature immunological synapse leads to concentration of the TCR at the APC interface. In this study, we show that the CD40-CD154 receptor-ligand pair is also highly concentrated into a central region of the synapse on mouse lymphocytes only after the formation of the TCR/CD3 c-SMAC. Concentration of this ligand was strictly dependent on TCR recognition, the binding of ICAM-1 to T cell integrins and the presence of an intact cytoskeleton in the T cells. This may provide a novel explanation for the specificity of T cell help directing the help signal to the site of Ag receptor signal. It may also serve as a site for these molecular aggregates to coassociate and/or internalize alongside other signaling receptors. The Journal of Im- munology, 2004, 173: 3647–3652. uring the onset and propagation of immune responses, T Interactions of T cells with Ag-bearing APCs is associated with cells send and receive signals via Ag-dependent and Ag- a coalescence of TCRs, other related receptors such as CD2, CD4, independent ligands. Whereas peptide-class II MHC CD28, and signaling molecules such as p56lck, fyn, linker for ac- D ϩ complexes on APC are recognized by the TCR on CD4 helper T tivation of T cells, and protein kinase C␪ into the central portion of cells, separate cell surface receptors modulate T cell-APC inter- an “immunological synapse” (15–23).
    [Show full text]
  • Processing Epitope Precursor Recognition and Analogue Provides
    The Journal of Immunology Crystal Structure of Insulin-Regulated Aminopeptidase with Bound Substrate Analogue Provides Insight on Antigenic Epitope Precursor Recognition and Processing Anastasia Mpakali,* Emmanuel Saridakis,* Karl Harlos,† Yuguang Zhao,† Athanasios Papakyriakou,* Paraskevi Kokkala,*,‡ Dimitris Georgiadis,‡ and Efstratios Stratikos* Aminopeptidases that generate antigenic peptides influence immunodominance and adaptive cytotoxic immune responses. The mechanisms that allow these enzymes to efficiently process a vast number of different long peptide substrates are poorly understood. In this work, we report the structure of insulin-regulated aminopeptidase, an enzyme that prepares antigenic epitopes for cross- presentation in dendritic cells, in complex with an antigenic peptide precursor analog. Insulin-regulated aminopeptidase is found in a semiclosed conformation with an extended internal cavity with limited access to the solvent. The N-terminal moiety of the peptide is located at the active site, positioned optimally for catalysis, whereas the C-terminal moiety of the peptide is stabilized along the extended internal cavity lodged between domains II and IV. Hydrophobic interactions and shape complementarity enhance peptide affinity beyond the catalytic site and support a limited selectivity model for antigenic peptide selection that may underlie the generation of complex immunopeptidomes. The Journal of Immunology, 2015, 195: 2842–2851. ytotoxic adaptive immune responses rely on the recogni- process, and present external Ags onto MHCI to allow cross-priming tion on the cell surface of complexes of MHC class I of naive CD8+ T cells (2). The cross-presentation pathway is key for C molecules (MHCI) with antigenic peptides. These peptides the immune defense against many viruses, bacteria, and tumors and are generated inside the cell by proteolytic digestion that often can help the immune system avoid immune evasion strategies.
    [Show full text]
  • Efficient Generation of Human Natural Killer Cell Lines by Viral Transformation
    Letters to the Editor 192 2 Department of Immunology, Erasmus MC, Erasmus University selected children with hypoplastic refractory cytopenia. Haematologica 2007; 92: Medical Center, Rotterdam, The Netherlands; 397–400. 3Department of Pediatrics and Adolescent Medicine, Division of 4 Dunn DE, Tanawattanacharoen P, Boccuni P, Nagakura S, Green SW, Kirby MR Pediatric Hematology and Oncology, University of Freiburg, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow Freiburg, Germany; failure syndromes. Ann Intern Med 1999; 131: 401–408. 4Department of Pathology, Clinical Centre South West, Bo¨blingen 5 Maciejewski JP, Follmann D, Nakamura R, Saunthararajah Y, Rivera CE, Simonis T et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal Clinics, Bo¨blingen, Germany; 5 hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 2001; 98: Department of Clinical Genetics, Erasmus MC, Erasmus University 3513–3519. Medical Center, Rotterdam, The Netherlands; 6 Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor 6 St. Anna Children’s Hospital and Children’s Cancer Research Institute, population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow Department of Pediatrics, Medical University of Vienna, failure syndrome. Blood 2002; 100: 3897–3902. Vienna, Austria; 7 Yoshida N, Yagasaki H, Takahashi Y, Yamamoto T, Liang J, Wang Y et al. 7Department of Pediatrics, Aarhus University Hospital Skejby, Clinical impact of HLA-DR15, a minor population of paroxysmal Aarhus, Denmark; nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated auto- 8Department of Pediatric Hematology-Oncology, IRCCS Ospedale antibody in children with acquired aplastic anaemia. Br J Haematol 2008; 142: 427–435.
    [Show full text]
  • And CD28 (T P44) Induces Autocrine Interleukin 2/Interleukin 2 Receptor-Mediated Cell Proliferation
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central A NOVEL ACTIVATION PATHWAY FOR MATURE THYMOCYTES Costimulation of CD2 (T,p50) and CD28 (T p44) Induces Autocrine Interleukin 2/Interleukin 2 Receptor-mediated Cell Proliferation By SOO YOUNG YANG, STEPHEN M. DENNING,' SHINICHI MIZUNO, BO DUPONT, AND BARTON F. HAYNES* From the Laboratories of Human and Biochemical Immunogenetics, Sloan-Kettering Institute for Cancer Research, New York, New York 10021; and the "Department of Medicine, Division of Rheumatology, Immunology, and Cardiology, Duke University School of Medicine, Durham, North Carolina 27710 Bone marrrow-derived T progenitor cells undergo proliferation and maturation under the influence of the thymic microenvironment (1). Only a small fraction of thymocytes are selected to account for self tolerance, as well as self restriction, and become immunocompetent T cells (2). The molecular and cellular mechanisms for the growth and maturation of thymocytes are poorly understood. Cell surface phenotype analyses have shown that thymocytes are composed ofhighly heterogeneous populations. Based on cell surface expression of the TCR accessory molecules CD4 and CD8, thymocytes can be divided into three major subpopula- tions, which generally are thought to relate to maturation stages. They are the CD2+CD1 - CD4- 8- (double-negative) cells, CD2'CD1'CD4'8' (double-positive) cells, and CD2' CDl - CD4' 8- or CD2' CDl - CD4- 8' (single-positive) mature thymocytes. Both double-negative and double-positive thymocytes are immature cells located in the cortical compartment of human thymus (3). Mature thymocytes do not express the cortical specific marker CD1 but express TCRA and B chain subunits associated with the CD3 complex and reside predominantly in the medullary com- partment (4) .
    [Show full text]
  • Integrins As Therapeutic Targets: Successes and Cancers
    cancers Review Integrins as Therapeutic Targets: Successes and Cancers Sabine Raab-Westphal 1, John F. Marshall 2 and Simon L. Goodman 3,* 1 Translational In Vivo Pharmacology, Translational Innovation Platform Oncology, Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany; [email protected] 2 Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK; [email protected] 3 Translational and Biomarkers Research, Translational Innovation Platform Oncology, Merck KGaA, 64293 Darmstadt, Germany * Correspondence: [email protected]; Tel.: +49-6155-831931 Academic Editor: Helen M. Sheldrake Received: 22 July 2017; Accepted: 14 August 2017; Published: 23 August 2017 Abstract: Integrins are transmembrane receptors that are central to the biology of many human pathologies. Classically mediating cell-extracellular matrix and cell-cell interaction, and with an emerging role as local activators of TGFβ, they influence cancer, fibrosis, thrombosis and inflammation. Their ligand binding and some regulatory sites are extracellular and sensitive to pharmacological intervention, as proven by the clinical success of seven drugs targeting them. The six drugs on the market in 2016 generated revenues of some US$3.5 billion, mainly from inhibitors of α4-series integrins. In this review we examine the current developments in integrin therapeutics, especially in cancer, and comment on the health economic implications of these developments. Keywords: integrin; therapy; clinical trial; efficacy; health care economics 1. Introduction Integrins are heterodimeric cell-surface adhesion molecules found on all nucleated cells. They integrate processes in the intracellular compartment with the extracellular environment. The 18 α- and 8 β-subunits form 24 different heterodimers each having functional and tissue specificity (reviewed in [1,2]).
    [Show full text]